fbpx
Industry Session
A clinical manifesto on SGLT2 inhibitors in patients with heart failure
Monday July 13, 2020: 7:00PM – 8:30 PM EDT (GMT -4)
anker
STEFAN ANKER
(Germany)
coats
ANDREW COATS
(UK)
Martin-Cowie-
MARTIN COWIE
(UK)
Nikolaus-Marx
NIKOLAUS MARX
(UK)
Zieroth-a-espace
SHELLEY ZIEROTH
(Canada)
AGENDA:
  • Health: SGLT2 inhibitors and quality of life – Martin Cowie, Shelley Zieroth
  • Protect: SGLT2 inhibitors in patients with HF – Martin Cowie, Nikolaus Marx
  • Wealth: An abundance (and more to come) of SGLT2 inhibitor evidence – Stefan Anker, Andrew Coats
LEARNING OBJECTIVES:
  • Encourage conversation around SGLT2 inhibitors as cardiovascular therapies with cardio–renal benefits
  • Highlight and discuss profiles of appropriate patients for initiation of an SGLT2 inhibitor, and share with cardiologists the well-established safety profile of and the clinical considerations for treatment with an SGLT2 inhibitor
  • Inform cardiologists of the current evidence and ongoing trials for SGLT2 inhibitors in patients with heart failure
Looking to register a group of 10 or more? contact: “[email protected]”.

Thank You!